

CLAIMS

1. A nucleic acid comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing.

5 2. The nucleic acid according to claim 1, comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing.

3. A nucleic acid complementary to the nucleic acid according to claim 1 or 2.

10 4. A nucleic acid capable of hybridizing to the nucleic acid according to any of claims 1-3 under stringent conditions.

5. A nucleic acid probe comprising nucleic acid (a) or nucleic acid (b):

15 (a) a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing, or a nucleic acid complementary thereto;

20 (b) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing, or a nucleic acid complementary thereto.

6. The nucleic acid probe according to claim 5, comprising nucleic acid (a) or nucleic acid (b):

25 (a) a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences

set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing, or a nucleic acid complementary thereto;

(b) a nucleic acid capable of hybridizing under stringent conditions to a nucleic acid comprising a partial length or the full length of one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing, or a nucleic acid complementary thereto.

7. A diagnostic agent for stage 4s neuroblastoma comprising the nucleic acid probe according to claim 5 or 6 as the active ingredient.

8. A primer containing DNA (a) or DNA (b):

(a) a DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:1076 in the Sequence Listing, or a DNA complementary thereto;

(b) a DNA capable of hybridizing under stringent conditions to the DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:1076 in the Sequence Listing, or a DNA complementary thereto.

9. A primer containing DNA (a) or DNA (b):

(a) a DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:202 and SEQ ID NO:519 to SEQ ID NO:540 in the Sequence Listing, or a DNA complementary thereto, or a DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:785 to SEQ ID NO:798 in the Sequence Listing, or a DNA complementary thereto;

(b) a DNA capable of hybridizing under stringent conditions to the

DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:175 to SEQ ID NO:202 and SEQ ID NO:519 to SEQ ID NO:540 in the Sequence Listing or a DNA comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:785 to SEQ ID NO:798 in the Sequence Listing, or a DNA complementary thereto.

10. A diagnostic kit for stage 4s neuroblastoma comprising one pair of the primers according to claims 8 or 9 as the active component.

11. A method for determining stage 4s neuroblastoma, the method comprising detecting the presence or absence of a nucleic acid comprising one sequence selected from the group consisting of nucleic acid sequences set forth in SEQ ID NO:1 to SEQ ID NO:14 in the Sequence Listing from a clinical tissue sample of neuroblastoma.

12. A nucleic acid microarray comprising a solid phase support and a combination of plural nucleic acids each comprising a partial length- or the full length-nucleic acid comprising a nucleic acid sequence set forth in one of SEQ ID NO:1 to SEQ ID NO:174 in the Sequence Listing immobilized on the solid phase support.

13. A nucleic acid microarray comprising a solid phase support and a combination of plural nucleic acids each comprising a nucleic acid sequence set forth in one of SEQ ID NO:175 to SEQ ID NO:200, a nucleic acid sequence set forth in one of SEQ ID NO:519 to SEQ ID NO:540 or a nucleic acid sequence set forth in one of SEQ ID NO:785 to SEQ ID NO:798 immobilized on the solid phase support.